Skip to main content
  •   Home
  •   Download
  •   Manual
  •   Contact

Drug Details

General Information of the Drug (ID: DR0221)
Name
2-deoxy-D-glucose
Synonyms
154-17-6; Deoxyglucose; 2-Desoxy-D-glucose; 2-DG; 2-Deoxy-D-arabinohexose; 2-Deoxy-D-mannose; D-2-Deoxyglucose; (3R,4S,5R)-3,4,5,6-tetrahydroxyhexanal; arabino-Hexose, 2-deoxy-; UNII-9G2MP84A8W; D-Arabino-hexose, 2-deoxy-; HSDB 5484; D-Glucose, 2-deoxy-; 9G2MP84A8W; 2 Deoxyglucose; 2 Deoxy D glucose; 2 Desoxy D glucose; D-arabino-2-desoxyhexose; 2-Desoxy-D-glucose [French]; CCRIS 9094; MFCD00151328; d-2-glucodesose; EINECS 205-823-0; D-2dGlc; BRN 1723331; deoxy-d-glucose, 2-; 2-DEOXYLGLUCOSE; SCHEMBL7670; 4-01-00-04282 (Beilstein Handbook Reference); CHEMBL2074932; DTXSID1037648; ALBB-022735; AMY10934; ZINC2512351; ANW-21488; CD0012; AKOS015919409; AKOS015924825; DB08831; LS30109; 2-Deoxy-D-glucose, BioXtra, >=98%; AS-12502; AB0012037; DB-024740; D0051; 54D176; D-arabino-Hexose, 2-deoxy- (6CI,8CI,9CI); S-1013; 2-Deoxy-D-glucose, >=98% (GC), crystalline; 2-Deoxy-D-glucose, >=99% (GC), crystalline; Q3266534; 5CFA0332-FB70-485D-A064-6C4C39E7CBA1; 2-Deoxy-D-glucose, United States Pharmacopeia (USP) Reference Standard
    Click to Show/Hide
Molecular Type
Small molecule
Disease Solid tumour/cancer [ICD-11: 2A00-2F9Z] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C6H12O5
PubChem CID
108223
Canonical SMILES
C(C=O)C(C(C(CO)O)O)O
InChI
1S/C6H12O5/c7-2-1-4(9)6(11)5(10)3-8/h2,4-6,8-11H,1,3H2/t4-,5-,6+/m1/s1
CAS Number
CAS 154-17-6
TTD Drug ID
D0H3KI
DrugBank ID
DB08831
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Arsenic trioxide      Realgar and orpiment     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation
Down-regulation Expression AKT1  Molecule Info 
Pathway MAP
Down-regulation Phosphorylation AKT1  Molecule Info 
Pathway MAP
Down-regulation Expression BAX  Molecule Info 
Pathway MAP
Up-regulation Expression BAX  Molecule Info 
Pathway MAP
Down-regulation Expression BID  Molecule Info 
Pathway MAP
Up-regulation Cleavage CASP3  Molecule Info 
Pathway MAP
Up-regulation Cleavage CASP9  Molecule Info 
Pathway MAP
Down-regulation Phosphorylation ERK1  Molecule Info 
Pathway MAP
Up-regulation Phosphorylation MEK1  Molecule Info 
Pathway MAP
Down-regulation Phosphorylation PRKAA2  Molecule Info 
Pathway MAP
Up-regulation Phosphorylation S6K1  Molecule Info 
Pathway MAP
Down-regulation Phosphorylation STK11  Molecule Info 
Pathway MAP
Down-regulation Expression XIAP  Molecule Info 
Pathway MAP
                    Biological
                    Regulation
Up-regulation Cytochrome c release
                    In-vitro Model HL-60 CVCL_0002 Adult acute myeloid leukemia Homo sapiens
U-937 CVCL_0007 Adult acute monocytic leukemia Homo sapiens
NB4 CVCL_0005 Acute promyelocytic leukemia Homo sapiens
THP-1 CVCL_0006 Childhood acute monocytic leukemia Homo sapiens
                    Experimental
                    Result(s)
2-Deoxy-D-glucose cooperates with arsenic trioxide to induce apoptosis in leukemia cells: Involvement of IGF-1R-regulated Akt/mTOR, MEK/ERK and LKB-1/ AMPK signaling pathways.
          Metformin      Galega officinalis     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [3]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model VOA1056 CVCL_V536 Adenocarcinoma Homo sapiens
VOA1312 CVCL_V538 Adenocarcinoma Homo sapiens
VOA5646 CVCL_VQ39 Adenocarcinoma Homo sapiens
                    Experimental
                    Result(s)
2-DG significantly inhibited glycolysis in all LGSOC lines and combination with metformin showed synergistic inhibitory effect.
          Tephrosin      Tephrosia vogelii     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [4]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model HeLa CVCL_0030 Endocervical adenocarcinoma Homo sapiens
HT-29 CVCL_0320 Colon adenocarcinoma Homo sapiens
SW620 CVCL_0547 Colon adenocarcinoma Homo sapiens
A-549 CVCL_0023 Lung adenocarcinoma Homo sapiens
                    Experimental
                    Result(s)
The combination of TSN and 2-DG increased the sensitivity of cancer cells to 2-DG.
References
Reference 1 ClinicalTrials.gov (NCT00633087) A Phase I/II Trial of 2-Deoxyglucose (2DG) for the Treatment of Advanced Cancer and Hormone Refractory Prostate Cancer. U.S. National Institutes of Health.
Reference 2 2-Deoxy-D-glucose cooperates with arsenic trioxide to induce apoptosis in leukemia cells: involvement of IGF-1R-regulated Akt/mTOR, MEK/ERK and LKB-1/AMPK signaling pathways. Biochem Pharmacol. 2012 Dec 15;84(12):1604-16.
Reference 3 Synergistic effect of MEK inhibitor and metformin combination in low grade serous ovarian cancer. Gynecol Oncol. 2017 Aug;146(2):319-326.
Reference 4 The combination of tephrosin with 2-deoxy-D-glucose enhances the cytotoxicity via accelerating ATP depletion and blunting autophagy in human cancer cells. Cancer Biol Ther. 2011 Dec 1;12(11):989-96.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
Cite NPCDR
Visitor Map
Correspondence

X. N. Sun, Y. T. Zhang, Y. Zhou, X. C. Lian, L. L. Yan, T. Pan, T. Jin, H. Xie, Z. M. Liang, W. Q. Qiu, J. X. Wang, Z. R. Li, F. Zhu*, X. B. Sui*. NPCDR: natural product-based drug combination and its disease-specific molecular regulation. Nucleic Acids Research. 50(D1): 1324-1333 (2020). PMID: 34664659

Prof. Feng ZHU  (zhufeng@zju.edu.cn)

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China


Prof. Xinbing SUI  (hzzju@hznu.edu.cn)

School of Pharmacy and Department of Medical Oncology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China